Cantor Fitzgerald Comments on Humana FY2026 Earnings

Humana Inc. (NYSE:HUM) – Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Humana in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst S. James expects that the insurance provider will earn $14.58 per share for the year. Cantor Fitzgerald currently has a “Neutral” rating and a $290.00 target price on the stock. The consensus estimate for Humana’s current full-year earnings is $16.47 per share.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, topping the consensus estimate of $10.07 by $1.51. Humana had a net margin of 1.02% and a return on equity of 11.70%. The firm had revenue of $32.11 billion for the quarter, compared to analysts’ expectations of $32 billion. During the same quarter last year, the firm earned $7.23 EPS. The company’s quarterly revenue was up 8.4% compared to the same quarter last year.

HUM has been the subject of several other research reports. Guggenheim assumed coverage on Humana in a report on Wednesday, April 9th. They issued a “buy” rating and a $326.00 price objective for the company. Royal Bank of Canada restated an “outperform” rating and set a $283.00 price target on shares of Humana in a research note on Wednesday, February 12th. Robert W. Baird boosted their target price on shares of Humana from $270.00 to $300.00 and gave the company a “neutral” rating in a report on Tuesday, April 15th. Raymond James upgraded Humana from a “market perform” rating to an “outperform” rating and set a $315.00 price target for the company in a research report on Thursday, May 1st. Finally, Oppenheimer increased their price objective on Humana from $300.00 to $310.00 and gave the stock an “outperform” rating in a report on Thursday, May 1st. Sixteen equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $284.48.

Humana Stock Down 0.5%

Humana stock opened at $231.95 on Tuesday. Humana has a twelve month low of $212.45 and a twelve month high of $406.46. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The firm has a 50 day moving average price of $252.19 and a 200-day moving average price of $264.01. The company has a market capitalization of $27.99 billion, a P/E ratio of 23.31, a P/E/G ratio of 2.05 and a beta of 0.43.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be paid a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.53%. The ex-dividend date is Friday, June 27th. Humana’s dividend payout ratio is currently 25.04%.

Institutional Trading of Humana

Large investors have recently made changes to their positions in the stock. FPC Investment Advisory Inc. bought a new stake in Humana in the 4th quarter worth approximately $27,000. Centricity Wealth Management LLC bought a new position in Humana in the fourth quarter valued at about $30,000. Cary Street Partners Investment Advisory LLC boosted its position in Humana by 63.9% in the first quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider’s stock worth $31,000 after purchasing an additional 46 shares during the last quarter. LFA Lugano Financial Advisors SA grew its stake in shares of Humana by 56.3% during the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock valued at $32,000 after purchasing an additional 45 shares during the period. Finally, OFI Invest Asset Management purchased a new stake in shares of Humana during the 4th quarter valued at about $33,000. 92.38% of the stock is currently owned by institutional investors.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.